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Summary
Background Deaths in HIV-positive people have decreased since the introduction of highly active antiretroviral therapy 
(HAART) in 1996. Fewer AIDS-related deaths and an ageing cohort have resulted in an increase in the proportion of 
HIV patients dying from non-AIDS-related disorders. Here we describe mortality and causes of death in people 
diagnosed with HIV in the HAART era compared with the general population.
Methods In this observational analysis, we linked cohort data collected by Public Health England (PHE) for individuals 
aged 15 years and older, diagnosed with HIV in England and Wales from 1997 to 2012, to the Oﬃ  ce for National 
Statistics (ONS) national mortality register. Cohort inclusion began at diagnosis with follow-up clinical information 
collected every year from all 220 National Health Service (NHS) HIV outpatient clinics nationwide. To classify causes 
of death we used a modiﬁ ed Coding Causes of Death in HIV (CoDe) protocol, which uses death certiﬁ cate data and 
clinical markers. We applied Kaplan-Meier analysis for survival curves and mortality rate estimation and Cox 
regression to establish independent predictors of all-cause mortality, adjusting for sex, infection route, age at 
diagnosis, region of birth, year of diagnosis, late diagnosis, and history of HAART. We used standardised mortality 
ratios (SMRs) to make comparisons with the general population.
Findings Between 1997 and 2012, 88 994 people were diagnosed with HIV, contributing 448 839 person-years of 
follow up. By the end of 2012, 5302 (6%) patients had died (all-cause mortality 118 per 10 000 person-years, 
95% CI 115–121). In multivariable analysis, late diagnosis was a strong predictor of death (hazard ratio [HR] 3·50, 
95% CI 3·13–3·92). People diagnosed more recently had a lower risk of death (2003–07: HR 0·66, 95% CI 0·62–0·70; 
2008–12: HR 0·65, 95% CI 0·60–0·71). Cause of death was determinable for 4808 (91%) of 5302 patients; most 
deaths (2791 [58%] of 4808) were attributable to AIDS-deﬁ ning illnesses. Cohort mortality was signiﬁ cantly higher 
than the general population for all causes (SMR 5·7, 95% CI 5·5–5·8), particularly non-AIDS infections (10·8, 
9·8–12·0) and liver disease (3·7, 3·3–4·2). All-cause mortality was highest in the year after diagnosis (SMR 24·3, 
95% CI 23·4–25·2).
Interpretation Despite the availability of free treatment and care in the UK, AIDS continues to account for the majority 
of deaths in HIV-positive people, and mortality remains higher in HIV-positive people than in the general population. 
These ﬁ ndings highlight the importance of prompt diagnosis, care engagement, and optimum management of 
comorbidities in reducing mortality in people with HIV.
Funding Public Health England.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Since highly active antiretroviral therapy (HAART) was 
introduced in the UK in 1996, mortality in HIV-positive 
people has decreased substantially and modelling 
suggests that life expectancy of those diagnosed soon 
after infection and started on treatment is approaching 
that of the general population.1,2 In the UK, the annual 
number of deaths in the HIV-positive population fell 
from 1730 in 1995, to 490 in 2012,3 largely because of a 
reduction in deaths from AIDS.2 Fewer AIDS-related 
deaths and an ageing cohort have resulted in an 
increase in the proportion of HIV patients dying from 
non-AIDS-related disorders, such as cardiovascular 
disease (CVD), cancer, and liver disease.4,5
Monitoring causes of death in HIV-positive people 
enables appropriate targeting of interventions to improve 
the quality of patient care and reduce avoidable mortality. 
In England and Wales, all deaths are reported to the 
national mortality register. These reports are linked every 
year to the comprehensive national cohort of people 
diagnosed with HIV and accessing care under the National 
Health Service (NHS). By the end of 2012, 77 610 people 
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diagnosed with HIV were under active follow up, providing 
a unique opportunity to track all-cause mortality in the 
HAART era.3
The Coding Causes of Death in HIV (CoDe) protocol 
standardises the classiﬁ cation of causes of death in 
HIV-positive people using death certiﬁ cate data and 
clinical markers and is used widely in Europe and 
the USA.4–6 In this study, a modiﬁ ed CoDe protocol was 
applied to describe causes of death among people 
diagnosed with HIV, changes in mortality in the era 
of HAART, and compare mortality with the general 
population.
Methods
Data sources
Public Health England (PHE) collects cohort data for all 
people diagnosed with HIV in the UK as part of the 
national HIV surveillance programme. Cohort inclusion 
begins at diagnosis with follow-up clinical information 
collected every year from all 220 NHS HIV outpatient 
clinics nationwide.
Patient data are annually linked to the Oﬃ  ce for 
National Statistics (ONS) death data, using pseudo-
anonymised identiﬁ ers. ONS provides PHE with all-cause 
death data by death-year for people who died before the 
Research in context
Evidence before this study
To assess the research comparing mortality of HIV-positive 
people to the general population, we searched Ovid MEDLINE 
up to Feb 24, 2016, including in-process and other non-indexed 
citations published in all languages. Search terms included: 
(MeSH headings: “HIV/” or “HIV-2/” or “HIV-1/” or “HIV 
Infections/” or “Acquired Immunodeﬁ ciency Syndrome/”) OR 
(keywords in title/abstract: “HIV” or “HIV infect*” or “HIV 
patient” or “HIV 1” or “HIV 2” or “HIV 1 infect*” or “HIV 2 
infect*” or “human immunodeﬁ ciency virus” or “acquired 
immune deﬁ ciency syndrome” or “acquired immunodeﬁ ciency 
syndrome” or “AIDS”) AND (keywords in title/abstract: 
“standardised mortality” or “standardized mortality”).
There were 152 search results of which 20 were eligible for 
further review, from western countries and presenting 
standardised mortality ratios (SMRs). Estimates varied widely 
between studies and countries and the ability to compare was 
dependent upon the SMR stratiﬁ cations (all-cause vs 
breakdown by sex, cause of death, clinical markers, and so on). 
Of the 20 included studies, 13 described mortality among 
patients enrolled in HIV care and undergoing routine 
follow-up, with six focusing solely on those patients receiving 
antiretroviral therapy (ART) (Collaboration of Observational 
HIV Epidemiological Research Europe [COHERE], Antiretroviral 
Therapy Cohort Collaboration [ARTCC], Agence Nationale de 
Recherches sur le Sida et les hepatites virales [ANRS], 
BC Centre for Excellence Drug Treatment Program, Australia 
HIV Observational Database, International Study to Evaluate 
Recombinant Interleukin-2 in HIV Positive Patients Taking 
Antiretroviral Therapy [ESPRIT]/ Comparison of Two Ways to 
Manage Anti-HIV Treatment [SMART]). Where all-cause SMRs 
were presented for those on treatment, mortality of 
HIV-positive patients was 1·2-4·2 times that of the general 
population, excluding the one study from the ANRS cohort 
which estimated mortality to be as high as 7·0 (95% CI 
6·2-7·8) among patients starting treatment with 
protease inhibitors.
Four studies described mortality and calculated SMRs using 
case-based surveillance matched to mortality data from a vital 
statistics register or death reports. One small study 
(n=210 deaths), in Spain, estimated all-cause mortality of 
20–59 year olds diagnosed with HIV between 1999 and 2006 to 
be 14 times that of the general population, while a slightly 
larger Italian study (n=1211) found the all-cause mortality SMR 
to be 6·0 (SMR 4·5 men and 9·4 women). The two remaining 
surveillance studies (in San Francisco, CA, USA) estimated 
mortality in men diagnosed with HIV from 1994–1998 
(n=5234) and 1996–2011 (n=5538) compared with the general 
population. Rather than all-cause mortality, results were 
stratiﬁ ed by cause of death. The more recent of the two studies 
showed an increased risk of death from non-AIDS cancers, 
heart, and liver disease in people with HIV compared with the 
general male population.
Added value of this study
To the best of our knowledge, this is the largest study to 
compare mortality of HIV-positive people diagnosed in the era 
of eﬀ ective HAART with that of the general population, and 
the only study up to now to present standardised mortality 
ratios by both cause of death and sex. Our ﬁ ndings are based 
on a comprehensive national cohort of all people diagnosed 
with HIV from the date of ﬁ rst diagnosis, including people that 
present late and those never linked to HIV care, usually missed 
in clinical HIV cohorts. The eﬀ ect of this inclusion on mortality 
is profound and can be seen in the high burden of AIDS deaths 
in our study population. Even when AIDS deaths were 
excluded, mortality in our cohort remained double that of the 
general population. In the ﬁ rst year post-diagnosis, mortality 
was 24 times higher, dropping to 2·8 that of the general 
population in subsequent years. Though survival was found to 
improve over time for the cohort, mortality compared with the 
general population was still elevated among those diagnosed 
in recent years.
Implications of all the available evidence
Data from treatment and care cohorts have provided evidence 
of the beneﬁ t of HAART in reducing mortality among the 
HIV-positive population. However, our data highlight the 
importance of prompt diagnosis and linkage to care in 
reducing mortality in the coming years, in addition to 
optimum prevention and management of comorbidities. 
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age of 65 years and AIDS-only death data for those aged 
65 years and older. Linkage is otherwise unreliable in 
those who died aged 65 years or older because of the high 
number of deaths in this age group. However, PHE also 
receives death reports, irrespective of age at death, from 
HIV clinicians through routine surveillance and annual 
death auditing. When cause of death was available from 
multiple sources, ONS data were used.
Death data for the general population in England and 
Wales by sex, age, and primary cause according to the 
10th revision of the International Statistical Classiﬁ cation 
of Diseases and Related Health Problems (ICD-10) by 
death year, were obtained from the ONS website, along 
with data for population size by sex and age.7
Population
People diagnosed with HIV between 1997 and 2012 in 
England and Wales, aged 15 years and older at diagnosis, 
were followed up to the end of 2012 (data extracted 
January, 2014). Analyses were restricted to people 
diagnosed in England and Wales due to the availability of 
comparable ONS data on causes of death in the general 
population in Scotland and Northern Ireland.
Deﬁ nitions
Late diagnosis was deﬁ ned as a CD4 count of less than 
350 cells per mm³ within 3 months of diagnosis. A patient 
was considered linked to care if they had at least one 
attendance in an HIV outpatient clinic after diagnosis.8
Categorisation of cause of death
Two independent reviewers (one epidemiologist [either SC 
or MK] and one public health physician [either AK or ME]) 
categorised deaths; senior HIV medical epidemiologists 
(VD, AKS, and AS) adjudicated discrepancies, as per the 
CoDe protocol.6 CoDe categories were adapted to account 
for the way HIV surveillance data are collected in the UK; 
clinical markers are reported to PHE at last HIV outpatient 
clinic attendance in a given year and might not reﬂ ect 
information at time of death.6,9
Deaths were categorised on the basis of reported cause. 
Data for clinical markers were considered where 
information was incomplete to distinguish AIDS and 
non-AIDS infections (appendix p 1).
Descriptive analyses
We used Pearson χ² tests to compare categorical variables, 
and Wilcoxon tests for continuous variables (signiﬁ cance 
p<0·01). Stratiﬁ cations by diagnosis year (1997–2002, 
2003–07, and 2008–12) were chosen based on signiﬁ cant 
changes that have occurred in the epidemiology of HIV 
in the UK over time: 1997–2002 represent the early years 
of HAART; in 2003, the number of people probably 
infected through heterosexual contact peaked and 
subsequently decreased because of changing patterns of 
migration; and in 2008, sex between men became the 
most common route of transmission (appendix p 2).
Statistical analysis
For Kaplan-Meier survival curves and mortality rate 
estimation, we used HIV diagnosis date as time of entry, 
and follow up was censored on either the death date or 
the date last seen for HIV care. For cause-speciﬁ c 
analyses, data were also censored at death date from any 
other or unknown cause. People who neither died nor 
were seen for HIV care after diagnosis were censored at 
entry (n=3820) and excluded from time-to-event analysis. 
However, these individuals were included in all 
Total 
(n=88 994)*
Men 
(n=56 593)
Women 
(n=32 400)
Median age at 
diagnosis (years)
34
(28–41)
36
(29–43)
32
(27–39)
Age at diagnosis (years)
15–24 9821 (11%) 5273 (9%) 4548 (14%)
25–34 35 196 (40%) 20 515 (36%) 14 681 (45%)
35–44 28 110 (32%) 19 132 (34%) 8977 (28%)
45–54 11 074 (12%) 8057 (14%) 3017 (9%)
55–64 3716 (4%) 2783 (5%) 933 (3%)
≥65 1077 (1%) 833 (2%) 244 (1%)
Year of diagnosis
1997–02 22 912 (26%) 14 839 (26%) 8072 (25%)
2003–07 35 462 (40%) 20 948 (37%) 14 514 (45%)
2008–12 30 620 (34%) 20 806 (37%) 9814 (30%)
Region of birth
UK 23142 (36%) 19 853 (50%) 3289 (13%)
Sub-Saharan Africa 29 622 (46%) 10 641 (27%) 18 981 (76%)
Other 12 062 (19%) 9323 (23%) 2739 (11%)
Infection route
Sex between men 33 992 (40%) 33 992 (62%) ··
Heterosexual 
contact
49 099 (57%) 18 686 (34%) 30 412 (97%)
Injecting drug use 2182 (3%) 1598 (3%) 584 (2%)
Other 736 (1%) 341 (1%) 395 (1%)
Median CD4 count at 
diagnosis 
(cells per mm3)
318
(144–503)
340
(159–529)
279
(128–451)
CD4 count at diagnosis (cells per mm3)
<50 7168 (12%) 4506 (11%) 2662 (12%)
50–99 4334 (7%) 2650 (7%) 1684 (8%)
100–199 8158 (14%) 4606 (12%) 3552 (17%)
200–349 13 656 (23%) 8358 (21%) 5298 (25%)
350–499 12 009 (20%) 8069 (21%) 3940 (18%)
≥500 15 595 (26%) 11 214 (29%) 4381 (20%)
Diagnosis with an 
AIDS-deﬁ ning illness
10 660 (12%) 6871 (12%) 3789 (12%)
Linked to HIV care 
after diagnosis†
83 883 (94%) 53 631 (95%) 30 252 (93%)
Data are n (%) or median (IQR) unless otherwise speciﬁ ed. Sex was reported for 
100% of individuals (n=88 993); age at diagnosis: 100% (n=88 994); year of 
diagnosis: 100% (88 994); country of birth: 73% (n=64 826); infection route: 97% 
(n=86 009); CD4 count at diagnosis: 69% (n=60 920). *Percentages may not 
total 100% because of rounding. †At least one attendance in an HIV outpatient clinic 
after diagnosis.8 
Table 1: Cohort characteristics
See Online for appendix
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descriptive analysis to understand the population 
diagnosed with HIV in the HAART era. The appendix 
provides more information about those who were not 
followed up (appendix p 3).
We used the log-rank test to compare survival between 
groups. We used Cox regression to determine inde-
pendent predictors of all-cause mortality, adjusting for 
sex, infection route, age at diagnosis, region of birth, year 
of diagnosis, late diagnosis, and history of HAART, 
because of missing data for treatment start date.
To compare the cohort mortality to the general 
population, we calculated standardised mortality ratios 
(SMRs) using 5-year age bands, stratifying by sex, cause 
of death, and time since diagnosis; 95% conﬁ dence 
intervals (CIs) were calculated using Poisson distribution. 
We applied the distribution of cause of death in the 
population for 1999 to the general population for the 
years 1997 and 1998 because ONS data for these 2 years 
were unavailable. All analyses were done with Stata 
(version 13.0).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The ﬁ rst ﬁ ve authors of this paper had full 
access to the data (SC, AK, SD, MK, and ME); the 
corresponding author (SC) had ﬁ nal responsibility to 
submit for publication.
Results
Between 1997 and 2012, 88 994 adults were diagnosed 
with HIV in England and Wales, contributing 
448 839 person-years of follow up (table 1; appendix 
pp 4, 5). 56 593 (64%) of 88 994 diagnoses were in men, 
of whom 19 853 (50%) of 39 817 were UK-born and 
33 992 (62%) of 54 617 acquired HIV through sex 
between men. Most women (18 981 [76%] of 25 009) 
were born in sub-Saharan Africa, acquiring HIV 
through heterosexual contact (30 412 [97%] of 31 391). 
Women were diagnosed at an earlier age (median age 
32 years in women vs 36 years in men) and a higher 
proportion were diagnosed late compared with men 
(61% women vs 51% men). From 1997 to 2012, HIV 
diagnoses rose continuously in men who have sex with 
men (MSM), people born in the UK, and all older age 
groups (appendix p 2). By contrast, diagnoses in 
heterosexuals, especially women, and those born in 
sub-Saharan Africa decreased from 2003 onwards. Late 
diagnosis decreased from 61% in 1997 to 46% in 2012 
(appendix p 2).
By the end of 2012, 5302 (6%) of 88 994 people in the 
cohort had died, representing an all-cause mortality rate 
of 118 per 10 000 person-years (95% CI 115–121; table 2). 
Survival probability of the whole cohort at 1, 5, 10, and 
15 years from diagnosis was 96% (95% CI 96·1–96·4), 
94% (93·7–94·1), 91% (91·0–91·6), and 88% (87·7–88·8), 
respectively. The ﬁ gure shows Kaplan-Meier survival 
Figure: Kaplan-Meier survival estimates by year of diagnosis
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estimates of changes in survival over time by diagnosis 
year group, and the appendix provides further 
breakdowns by sex, age at diagnosis, region of birth, 
probable exposure, and CD4 at diagnosis (pp 6–15). 
Overall, cohort survival improved signiﬁ cantly across 
diagnosis year groups (log-rank p<0·0001).
The rate of all-cause mortality was higher in men 
(130 per 10 000 person-years, 95% CI 126–134) than 
women (96·8, 92·2–102; table 2). Mortality increased 
with age at diagnosis and was higher in UK-born 
people than in those born elsewhere. People who inject 
drugs had the highest mortality rate (331 per 
10 000 person-years, 95% CI 297–369); mortality was 
lowest in heterosexual women (81·3, 79·6–85·9). 
Mortality in people with low CD4 counts at diagnosis 
was high (tables 2 and 3). People linked to HIV care 
after diagnosis had an all-cause mortality rate of 90·6 
per 10 000 person-years (95% CI 87·9–93·4).
In multivariable analysis, a high risk of death was 
associated with being diagnosed late (table 4). People 
exposed to HIV through injecting drug use, heterosexual 
contact, and other routes had a higher risk of death than 
men infected through sex between men. Risk increased 
with age at diagnosis. The highest risk of death was 
associated with never being on HAART. Being a woman 
and being born outside the UK were associated with a 
lower risk of death (table 4). People diagnosed more 
recently had a lower risk of death than those diagnosed in 
earlier years.
With regards to the clinical characteristics of people 
who died, 1916 (76%) of 2535 who died were diagnosed 
late, 1242 (23%) were never linked to HIV outpatient 
care, and 1386 (34%) of those in care never received 
HIV treatment (table 5). Compared with patients who 
accessed care known to have died, those never linked 
to care were more likely to be women (433/1242 [35%] 
vs 1142/4060 [28%]; p<0·0001) infected through 
heterosexual contact (493/791 [62%] vs 2155/3966 
[54%]; p<0·0001). Of those who attended care, there 
was no signiﬁ cant diﬀ erence in treatment coverage by 
sex, age, region of birth, or infection route. Median 
time to treatment was 3·4 months from diagnosis 
(IQR 3·2–3·7). Time to death was shorter in those 
never in outpatient care (1138 [92%] of 1242 deaths 
occurred within 1 year) compared with those in care, 
irrespective of treatment history (never on HAART: 
971 [70%] of 1386 deaths occurred within 1 year vs ever 
on HAART: 905 [34%] of 2674). Mortality in the 
ﬁ rst year after diagnosis was six times higher than 
subsequently (tables 6–8).
Of the 5302 cohort deaths, 4808 (91%) were classiﬁ able 
by cause with no diﬀ erence in cause ascertainment over 
time. Most deaths (2791 [58%]) were attributable to 
AIDS-deﬁ ning illnesses (table 2). Among 2017 non-
AIDS deaths (tables 2 and 3), most were due to cancer 
(388 [19%]) followed by: CVD/stroke (378 [19%]), 
infections (358 [18%]), liver disease (234 [12%]), 
substance misuse (121 [6%]), suicide (96 [5%]), accident 
(94 [5%]), and other causes (348 [17%]). The most 
common other causes were: lung embolus (69 [20%]), 
renal failure (52 [15%]), other respiratory diseases 
(37 [11%]), and chronic obstructive pulmonary disease 
(36 [10%]). Another 32 (9%) were iatrogenic (eg, due to 
drug toxicity or surgery complications).
Tables 2 and 3 show cause-speciﬁ c mortality rates by 
key descriptive variables. Mortality rates were higher for 
men and those born in the UK across all causes. People 
with lower CD4 counts and diagnosed at an older age had 
consistently higher mortality. People who inject drugs 
had higher mortality rates from liver disease, accident, 
and substance misuse compared to those infected 
through other routes. Mortality due to AIDS-deﬁ ning 
illnesses was the highest across all demographic 
characteristics (table 2).
Patients who died from AIDS had the lowest median 
CD4 count at diagnosis (65 cells/mm3, IQR 19–196), the 
highest proportion diagnosed late (1014/1164 [87%]), and 
Unadjusted Adjusted
Hazard ratio 
(HR)
95% CI p value Hazard ratio 
(HR)
95% CI p value 
Sex
Men 1·00 .. .. 1·00 .. ..
Women 0·75 0·71–0·79 <0·0001 0·73 0·66–0·82 <0·0001
Age at diagnosis 
(years)
15–24 1·00 .. .. 1·00 .. ..
25–34 1·71 1·48–1·98 <0·0001 1·62 1·29–2·02 <0·0001
35–44 2·95 2·56–3·40 <0·0001 2·50 2·01–3·12 <0·0001
45–54 4·85 4·18–5·62 <0·0001 4·24 3·38–5·33 <0·0001
55–64 8·71 7·44–10·19 <0·0001 6·82 5·31–8·77 <0·0001
≥65 19·03 15·98–22·66 <0·0001 11·33 8·36–15·36 <0·0001
Region of birth
UK 1·00 .. .. 1·00 .. ..
Sub-Saharan Africa 0·70 0·66–0·75 <0·0001 0·74 0·65–0·84 <0·0001
Other 0·69 0·63–0·76 <0·0001 0·65 0·57–0·75 <0·0001
Probable exposure
Sex between men 1·00 .. .. 1·00 .. ..
Heterosexual contact 1·15 1·08–1·22 <0·0001 1·22 1·07–1·38 0·003
Injecting drug use 3·43 3·05–3·86 <0·0001 3·84 3·15–4·67 <0·0001
Other exposure 2·20 1·73–2·78 <0·0001 2·16 1·47–3·15 <0·0001
Diagnosis year
1997–2002 1·00 .. .. 1·00 .. ..
2003–07 0·66 0·62–0·70 <0·0001 0·78 0·70–0·87 <0·0001
2008–12 0·65 0·60–0·71 <0·0001 0·55 0·48–0·63 <0·0001
Diagnosed late
No 1·00 .. .. 1·00 .. ..
Yes 2·41 2·20–2·64 <0·0001 3·50 3·13–3·92 <0·0001
Ever on HAART
Yes 1·00 .. .. 1·00 .. ..
No 5·99 5·66–6·33 <0·0001 7·02 6·29–7·82 <0·0001
Table 4 : Cox proportional hazards model for all-cause mortality
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lowest linkage to care of all causes (table 5). For those 
who died from AIDS who did attend for outpatient care, 
treatment uptake was low at 57%. Almost three-quarters 
of AIDS deaths occurred within 1 year of diagnosis 
compared with 37% of non-AIDS deaths (table 5).
During the study period, mortality of the HIV cohort 
was six times higher than the general population, 
matched by age and sex (SMR 5·7, 95% CI 5·5–5·8), and 
remained raised after excluding AIDS deaths (2·2, 
2·1–2·3; table 6). Cohort mortality was especially high for 
non-AIDS infections (SMR 10·8, 95% CI 9·8–12·0) 
followed by liver disease (3·7, 3·3–4·2) and substance 
misuse (2·6, 2·1–3·1). All-cause mortality in HIV-positive 
men was 4·9 times higher and HIV-positive women 
8·8 times higher than their general population 
counterparts. SMRs were highest for non-AIDS infections 
(SMR in men 8·8, 95% CI 7·7–10·1; in women 18·3, 
15·3–21·7) and liver disease (in men 3·6, 3·1–4·1; in 
women 4·1, 3·0–5·4).
Cohort mortality across all causes was much higher 
in the year after HIV diagnosis than later (all-cause: 
SMR 24·3, 95% CI 23·4–25·2 vs 2·8, 2·7–2·9) and for 
the most part remained higher than the general 
population for both time periods (tables 6–8). Only 
mortality due to non-AIDS cancers, CVD and stroke, 
and accidental death dropped to become similar to 
those in the general population after the ﬁ rst year of 
diagnosis. Mortality due to non-AIDS infections in 
women in the year following HIV diagnosis was 
64·0 times higher than the general population (95% CI 
49·3–81·7) and remained 10·7 times higher (8·2–13·6) 
in subsequent years (table 6). Mortality in women from 
accident, suicide, and substance misuse was similar to 
that of the general population in the ﬁ rst year after 
diagnosis and onwards (tables 6–8).
The appendix (pp 16–18) shows changes in cohort 
mortality in the year after diagnosis compared with the 
general population by diagnosis year. Even in more 
recent years, mortality in the ﬁ rst year was raised 
compared with the general population across all causes.
Discussion
While mortality in the subgroup of people diagnosed with 
HIV who are promptly linked to care and successfully 
All-cause 
mortality 
(n=5302)
AIDS
(n=2791)
Non-AIDS 
infections 
(n=358)
Non-AIDS 
cancers 
(n=388)
Cardiovascular 
disease and 
stroke (n=378)
Liver disease 
(n=234)
Accident 
(n=94)
Suicide 
(n=96)
Substance 
misuse 
(n=121)
Other causes 
(n=348)
Overall median age at death 43 (36–52) 42 (35–51) 44 (37–54) 50 (42–58) 46 (38–54) 44 (38–50) 38 (31–45) 38 (32–43) 36 (31–42) 45 (36–55)
Death within 1 month of 
diagnosis
1542 (29%) 1069 (38%) 94 (26%) 49 (13%) 71 (19%) 39 (17%) 13 (14%) 12 (13%) 12 (10%) 80 (23%)
Death within 1 year of 
diagnosis
3014 (57%) 2036 (73%) 160 (45%) 109 (28%) 152 (40%) 80 (34%) 25 (27%) 38 (40%) 28 (23%) 150 (43%)
Not linked to HIV care 
before death*
1242 (23%) 796 (29%) 73 (20%) 37 (10%) 64 (17%) 42 (18%) 8 (9%) 7 (7%) 8 (7%) 72 (21%)
Median age at death 43 (36–55) 44 (36–56) 41 (34–58) 50 (42–58) 43 (36–53) 46 (38–53) 32 (28–44) 39 (37–46) 39 (33–43) 46 (36–57)
Death within 1 month of 
diagnosis
871 (70%) 588 (74%) 61 (84%) 24 (65%) 42 (66%) 29 (69%) 4 (50%) 4 (57%) 5 (63%) 47 (65%)
Death within 1 year of 
diagnosis
1138 (92%) 770 (97%) 69 (95%) 33 (89%) 51 (80%) 37 (88%) 7 (88%) 6 (86%) 6 (75%) 60 (83%)
Linked to HIV care before 
death*
4060 (77%) 1995 (72%) 285 (80%) 351 (91%) 314 (83%) 192 (82%) 86 (92%) 89 (93%) 113 (93%) 276 (79%)
Ever on treatment 2674 (66%) 1190 (60%) 204 (72%) 282 (80%) 228 (73%) 138 (72%) 55 (64%) 55 (62%) 66 (58%) 206 (75%)
Median time to 
treatment (months)
3·4 
(3·2–3·7)
2·4 
(0·79–7·5)
3·0
(1·0–9·9)
4·5
(1·4–19)
3·6
(1·3–12)
6·0
(2·1–22)
8·3
(2·2–24)
4·1
(1·4–17)
12
(2·1–37)
3·9 
(1·2–11)
Median age at death 43 (37–52) 41 (35–49) 45 (39–55) 51 (43–58) 48 (40–57) 44 (39–49) 39 (34–48) 39 (34–44) 38 (32–42) 46 (38–56)
Death within 1 month 
of diagnosis
221 (8%) 146 (12%) 10 (5%) 15 (5%) 13 (6%) 6 (4%) 3 (6%) 0 3 (5%) 15 (7%)
Death within 1 year of 
diagnosis
905 (34%) 602 (51%) 45 (22%) 44 (16%) 53 (23%) 22 (16%) 5 (9%) 8 (15%) 7 (11%) 51 (25%)
Not on treatment 1386 (34%) 805 (40%) 81 (28%) 69 (20%) 86 (27%) 54 (28%) 39 (45%) 41 (46%) 47 (42%) 70 (25%)
Median age at death 41 (34–39) 41 (35–50) 40 (33–49) 48 (40–55) 42 (34–52) 40 (36–48) 35 (29–45) 33 (28–40) 34 (30–39) 40 (34–49)
Death within 1 month 
of diagnosis
450 (33%) 335 (42%) 23 (28%) 10 (15%) 16 (19%) 4 (7%) 5 (13%) 8 (20%) 4 (9%) 18 (26%)
Death within 1 year of 
diagnosis
971 (70%) 664 (83%) 46 (57%) 32(46%) 48 (56%) 21 (39%) 13 (33%) 24 (59%) 15 (32%) 39 (56%)
Data are n (%) or median (IQR). *At least one attendance in an HIV outpatient clinic following diagnosis.8 
Table 5 : Clinical characteristics and timing of death in patients who died by cause of death
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treated is nearing that of the general population,10 our 
ﬁ ndings show that overall, the HIV-positive population has 
a six times higher risk of death than the general population. 
Delays in testing, linkage to care, and treatment are major 
factors that contribute to this increased mortality.
Our ﬁ ndings are consistent with the scientiﬁ c literature 
showing that mortality in HIV-positive people has 
declined in the past 20 years.2,5 The improvement in 
survival recorded in this study is the result of 
improvements in treatment and earlier initiation,11 as 
well as a shift in HIV epidemiology. Changes in 
migration patterns in the UK in the past decade have led 
to both a decrease in the number of diagnoses in people 
born in sub-Saharan Africa and the proportion of people 
born in the sub-Saharan Africa diagnosed late.12 There 
has also been a decrease in late presentation in MSM 
associated with increased testing uptake and frequency.3,12
Unlike most observational cohort studies that typically 
enrol HIV patients in clinical care or on treatment,4–6,13 this 
study includes individuals from the point of diagnosis, 
capturing those who present late or never link to HIV 
outpatient care. The eﬀ ect of this inclusion can be seen in 
the high number of deaths in the cohort compared with 
those expected in the general population, even in recent 
years. Overall, all-cause mortality was 5·7 times higher 
than that of the general population of England and Wales, 
matched by age and sex. This ﬁ gure is much higher than 
mortality reported in international treatment cohorts which 
estimate mortality to be between 1·2 and 4·2 times higher 
than the general population over similar time periods.10,14,15 
However, it is consistent with another smaller surveillance 
study in Italy including HIV patients from diagnosis 
(overall SMR 6·0, 4·5 in men, 9·4 in women).16 Our 
ﬁ ndings also show that men had a higher overall death rate 
than women but paradoxically women had a higher SMR 
than men. This ﬁ nding is most likely because of higher 
deaths rates in younger men in the general population.7
When stratiﬁ ed by time since diagnosis, all-cause 
mortality of the cohort in the ﬁ rst year after diagnosis 
was as high as 24 times that of the general population, 
compared with only 2·8 times from 1 year after diagnosis 
onwards. Mortality remained raised across all causes, 
even among those diagnosed in recent years, probably 
because of continuing high rates of late presentation, 
also reported across other European countries,17 which 
substantially eﬀ ect survival early on. In the UK, people 
diagnosed late have a ten times higher risk of death 
within 1 year of diagnosis than those diagnosed 
promptly18 and 3·5 times the risk of death overall. 
Our results also suggest that late diagnosis remains a 
major predictor of death from all causes.
AIDS continues to account for the highest proportion 
of deaths despite the availability of free HIV treatment 
and care in the UK through the NHS. This is much 
higher than previously published estimates of AIDS 
deaths in people accessing care (58% vs 33–43%).2,19,20 
In this cohort, the vast majority (87·1%) of people who 
died from AIDS were diagnosed late and a high 
proportion never linked to HIV outpatient care (28·5%). 
National HIV testing guidelines recommend various 
strategies to increase testing thereby reducing late 
diagnosis, including testing of HIV indicator-conditions 
and expanded testing outside of specialist sexually 
transmitted infection clinics in areas with high 
diagnosed prevalence.21 However, a 2013 audit of these 
guidelines found adherence to be poor outside of sexual 
health and antenatal clinics.22 It is crucial that HIV 
testing rates be increased; these analyses show a 
substantial number of deaths could have been 
prevented through earlier detection and that clear 
referral pathways are needed to ensure that once 
Mortality rate per 
10 000 person-years
(95% CI)
Observed 
deaths
Expected 
deaths*
Standardised 
mortality ratio
(95% CI)
People diagnosed with HIV 448 839 person-years
All-cause mortality 118 (115–121) 5302 938 5·7 (5·5–5·8)
Non-AIDS deaths 44·9 (43·0–46·9) 2017 923 2·2 (2·1–2·3)
Non-AIDS infections 8·0 (7·2–8·9) 358 33 10·8 (9·8–12·0)
Non-AIDS cancers 8·6 (7·8–9·5) 388 300 1·3 (1·2–1·4)
Cardiovascular disease and stroke 8·4 (7·6–9·3) 378 223 1·7 (1·5–1·9)
Liver disease 5·2 (4·6–5·9) 234 63 3·7 (3·3–4·2)
Accident 2·1 (1·7–2·6) 94 68 1·4 (1·2–1·7)
Suicide 2·1 (1·8–2·6) 96 48 2·0 (1·6–2·4)
Substance misuse 2·7 (2·3–3·2) 121 47 2·6 (2·1–3·1)
Other causes 7·8 (7·0–8·6) 348 141 2·5 (2·2–2·7)
Men 286 166 person-years
All-cause mortality 130 (126–134) 3727 759 4·9 (4·8–5·1)
Non-AIDS deaths 52·4 (50·0–55·2) 1501 747 2·0 (1·9–2·1)
Non-AIDS infections 8·0 (7·1–9·1) 230 26 8·8 (7·7–10·1)
Non-AIDS cancers 9·9 (8·8–11·1) 284 222 1·3 (1·2–1·4)
Cardiovascular disease and stroke 10·1 (9·0–11·3) 289 196 1·5 (1·3–1·7)
Liver disease 6·5 (5·6–7·5) 185 52 3·6 (3·1–4·1)
Accident 2·7 (2·2–3·4) 78 59 1·3 (1·0–1·7)
Suicide 3·2 (2·6–3·9) 91 42 2·2 (1·7–2·7)
Substance misuse 3·8 (3·2–4·6) 109 40 2·7 (2·2–3·3)
Other causes 8·2 (7·2–9·3) 235 110 2·1 (1·9–2·4)
Women 162 673 person-years
All-cause mortality 96·8 (92·2–102) 1575 180 8·8 (8·3–9·1)
Non-AIDS deaths 31·7 (29·1–34·6) 516 177 2·9 (2·6–3·2)
Non-AIDS infections 7·9 (6·6–9·4) 128 7 18·3 (15·3–21·7)
Non-AIDS cancers 6·4 (5·3–7·7) 104 77 1·4 (1·1–1·6)
Cardiovascular disease and stroke 5·5 (4·4–6·7) 89 27 3·3 (2·6–4·1)
Liver disease 3·0 (2·2–4·0) 49 12 4·1 (3·0–5·4)
Accident 0·98 (0·60–1·6) 16 9 1·8 (1·0–2·9)
Suicide 0·31 (0·13–0·74) 5 6 0·83 (0·27–1·9)
Substance misuse 0·74 (0·41–1·3) 12 7 1·7 (0·89–3·0)
Other causes 6·9 (5·8–8·4) 113 32 3·5 (2·9–4·2)
*Numbers may not add up due to rounding.
Table 6: Crude and age-standardised mortality in HIV-positive individuals by sex, cause of death, and 
time since diagnosis
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diagnosed, patients are promptly linked to HIV care, as 
recommended by the British HIV Association.23
Non-AIDS disorders accounted for 42% of deaths 
overall, and after AIDS deaths were excluded, non-AIDS 
mortality in our cohort was double that of the general 
population. However, the risk of non-AIDS mortality was 
signiﬁ cantly lower for people who had been diagnosed 
with HIV for more than 1 year. Mortality due to cancer 
and CVD in this subgroup was equal to that of the general 
population, though still elevated overall. This is consistent 
with evidence that though the risk of non-AIDS mortality 
is lower for treated patients compared with untreated 
patients, the incidence of cancer, liver disease, and CVD 
remain higher in the HIV-positive population than in the 
general population.24,25 
The incidence of CVD and non-AIDS cancers might be 
higher in HIV-positive people because of chronic low-level 
inﬂ ammation, which can promote carcinogenesis.26 
Additionally, lifestyle risk factors, such as obesity and 
smoking, are prevalent in this population.27,28 Long-term 
HIV treatment might also be associated with increased 
CVD-related risk and serious adverse events, though our 
data show a diﬀ erence in CVD mortality between men 
and women and published evidence is inconsistent.29
Previous studies have reported HIV-positive women are 
at signiﬁ cantly higher risk of severe bacterial non-AIDS 
infections30 and hospital admission for non-AIDS 
infections compared with men.31 This is the ﬁ rst study to 
report higher mortality due to non-AIDS infections 
among HIV-positive women in the era of eﬀ ective 
treatment. These ﬁ ndings warrant further investigation.
The higher mortality due to liver disease in HIV-positive 
people compared with the general population, 
irrespective of the time from HIV diagnosis, is most 
likely multifactorial, including the use of hepatotoxic 
antiretroviral drugs compounded by co-infections and 
lifestyle factors, such as obesity and alcohol misuse.24 
High levels of substance misuse and depression among 
MSM diagnosed with HIV have been reported,32 and 
might account for the high cohort mortality due to 
suicide and overdose seen among men. In this study, 
suicide was ﬁ ve times higher than the general population 
in the year after diagnosis. This could even be an 
underestimate, as suicide death classiﬁ cation relied on 
death certiﬁ cate data on intent.
Our ﬁ ndings suggest that to further reduce avoidable 
mortality, there must be optimal detection of co-
morbidities among people living with HIV, particularly 
in the ﬁ rst year after diagnosis, such as routine screening 
for CVD risk, depression, drug and alcohol misuse, 
cognitive diﬃ  culties, and blood-borne viruses, as 
suggested by the British HIV Association.23 Prevention 
measures should be strengthened, including smoking 
cessation, nutritional support, and drug and alcohol 
counselling. Furthermore, given the low median age of 
death and CD4 count at diagnosis seen among patients 
dying from non-AIDS, reducing late diagnosis could also 
reduce premature deaths from these causes. Future work 
will examine predictors of non-AIDS mortality.
Strengths of this study include the large size, 
comprehensive national coverage of all HIV-positive 
people followed up from diagnosis, and the use of 
the internationally validated CoDe protocol in death 
classiﬁ cation. To our knowledge, this is the largest and 
most complete report on HIV mortality to date in the UK. 
However, by design, this study is subject to limitations 
inherent to all retrospective cohort studies, particularly 
those constructed from clinical databases. Analysis was 
restricted to available data, meaning that some factors of 
Mortality rate per 
10 000 person-years 
(95% CI)
Observed 
deaths
Expected 
deaths*
Standardised 
mortality ratio 
(95% CI)
People diagnosed with HIV 72 965 person-years
All-cause mortality 413 (399–428) 3014 124 24·3 (23·4–25·2)
Non-AIDS deaths 102 (94·6–109) 742 121 6·1 (5·7–6·6)
Non-AIDS infections 21·9 (18·8–25·6) 160 4 40·0 (34·0–46·7)
Non-AIDS cancers 14·9 (12·4–18·0) 109 36 3·0 (2·5–3·7)
Cardiovascular disease and stroke 20·8 (17·8–24·4) 152 28 5·4 (4·6–6·4)
Liver disease 11·0 (8·8–13·7) 80 8 10·0 (7·9–12·4)
Accident 3·4 (2·3–5·1) 25 12 2·1 (1·3–3·1)
Suicide 5·2 (3·8–7·1) 38 8 4·8 (3·4–6·5)
Substance misuse 3·8 (2·6–5·6) 28 7 4·0 (2·7–5·8)
Other causes 20·6 (17·5–24·1) 150 18 8·3 (7·1–9·8)
Men 46 660 person-years
All-cause mortality 437 (418–456) 2039 100 20·4 (19·5–21·3)
Non-AIDS deaths 110 (101–120) 515 99 5·2 (4·8–5·7)
Non-AIDS infections 20·6 (16·8–25·1) 96 4 24·0 (19·4–29·3)
Non-AIDS cancers 16·1 (12·8–20·2) 75 27 2·8 (2·2–3·5)
Cardiovascular disease and stroke 23·8 (19·8–28·7) 111 25 4·4 (3·7–5·3)
Liver disease 13·5 (10·5–17·3) 63 6 10·5 (8·1–13·4)
Accident 4·5 (2·9–6·9) 21 10 2·1 (1·3–3·2)
Suicide 7·9 (5·7–10·9) 37 7 5·3 (3·7–7·3)
Substance misuse 5·1 (3·4–7·7) 24 6 4·0 (2·6–6·0)
Other causes 18·9 (15·3–23·2) 88 14 6·3 (5·0–7·7)
Women 26 305 person-years
All-cause mortality 371 (348–395) 975 24 40·6 (38·1–43·3)
Non-AIDS deaths 86·3 (75·8–98·2) 227 24 9·5 (8·3–10·8)
Non-AIDS infections 24·3 (19·0–31·0) 64 1 64·0 (49·3–81·7)
Non-AIDS cancers 12·9 (9·2–18·0) 34 10 3·4 (2·4–4·8)
Cardiovascular disease and stroke 15·6 (11·5–21·2) 41 4 10·3 (7·4–13·9)
Liver disease 6·5 (4·0–10·4) 17 1 17·0 (9·9–27·2)
Accident 1·5 (0·57–4·1) 4 2 2·0 (0·54–5·1)
Suicide 0·38 (0·053–2·7) 1 1 1·0 (0·01–5·6)
Substance misuse 1·5 (0·57–4·1) 4 1 4·0 (1·1–10·2)
Other causes 23·6 (18·4–30·2) 62 4 15·5 (11·9–19·9)
*Numbers may not add up due to rounding.
Table 7: Crude and age-standardised mortality in HIV-positive individuals by sex, cause of death, in the 
ﬁ rst year after diagnosis 
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interest could not be explored, such as social and 
behavioural information. Death categorisation occurred 
retrospectively, relying on existing clinical and death 
information; the protocol was modiﬁ ed to consider 
clinical markers in the year before death, where 
information at time of death was unavailable. 
Misclassiﬁ cation was minimised through a rigorous 
adjudication process. History of HAART was used as a 
covariate in Cox regression as data on treatment start 
date were incomplete; as such, the eﬀ ect of HAART on 
survival should be interpreted with caution. Absence of 
available 1997–98 general population death data could 
have resulted in SMRs being overestimated.
In addition to missing data, diﬀ erential loss to follow 
up might have also led to bias, particularly through 
under-ascertainment of deaths occurring abroad. 
At least half of this cohort were born abroad, and an 
analysis of the 3503 individuals lost to follow up for 
more than 5 years before 2012 showed that the majority 
were sub-Saharan Africa born, heterosexual women, 
likely to have emigrated out of the country.33 Emigration 
data are not collected as part of national HIV 
surveillance and it is not possible to link to a national 
register. This was taken into consideration in the 
decision to right censor on the date last seen for care in 
the UK, which limited the analysis to conﬁ rmed 
follow-up time and excluded people with no follow up 
after diagnosis by default. Though this method of 
censorship might have resulted in higher mortality 
estimates, individuals are unlikely to remain well 
without accessing HAART through HIV specialist 
services for a long period of time, and given the high 
proportion of those lost to follow-up who were born 
abroad, we feel it is more likely that these people have 
either left the UK or record linkage was not possible 
due to coding errors in patient identiﬁ ers or name 
changes, resulting in duplicate patients.
Surveillance and death data might be subject to reporting 
delays and poor linking due to incomplete identiﬁ ers. 
Multiple reporting sources and triangulation of data 
reduce these biases. Over 95% of HIV-positive patients can 
be linked across clinics and calendar years in the UK.3 
Finally, whilst clinicians report all-cause mortality among 
patients regardless of age, reports received from ONS 
include all AIDS deaths and deaths from any cause in 
those aged <65 years. The number of deaths in those aged 
≥65 might therefore be under-reported and the mortality 
rates in this group should be interpreted with caution. The 
eﬀ ect of this reporting bias might be mitigated by the fact 
this group comprises only 3·0% of the cohort, 0·70% of 
the total cohort person-years, and that deaths might be 
captured through audits and clinician reports.
Despite the availability of free antiretroviral treatment 
in the UK, mortality in HIV-positive people continues to 
be higher than that of the general population, with 
AIDS being the leading cause of death. These ﬁ ndings 
highlight the importance of prompt diagnosis and 
linkage to care as major public health interventions to 
reduce premature mortality. HIV testing should be 
further expanded outside traditional settings to reach 
vulnerable populations and patients supported across the 
HIV care pathway. As people live longer with HIV, 
prevention and optimal management of comorbidities 
might further reduce mortality. Robust surveillance data 
for deaths and cause of death are crucial, as mortality is 
a key marker of the eﬀ ectiveness of a country’s HIV 
strategy and should be a standardised indicator in 
international HIV reporting.
Mortality rate per 
10 000 person-years
(95% CI)
Observed 
deaths
Expected 
deaths*
Standardised 
mortality ratio
(95% CI)
People diagnosed with HIV 375 874 person-years
All-cause mortality 60·8 (58·4–63·4) 2288 816 2·8 (2·7–2·9)
Non-AIDS deaths 33·9 (32·1–35·8) 1275 803 1·6 (1·5–1·7)
Non-AIDS infections 5·3 (4·6–6·1) 198 29 6·8 (5·9–7·8)
Non-AIDS cancers 7·4 (6·6–8·3) 279 264 1·1 (0·94–1·2)
Cardiovascular disease and stroke 6·0 (5·3–6·8) 226 195 1·2 (1·0–1·3)
Liver disease 4·1 (3·5–4·8) 154 56 2·8 (2·3–3·2)
Accident 1·8 (1·4–2·3) 69 56 1·2 (0·96–1·6)
Suicide 1·5 (1·2–2·0) 58 40 1·5 (1·1–1·9)
Substance misuse 2·5 (2·0–3·0) 93 40 2·3 (1·9–2·8)
Other causes 5·3 (4·6–6·1) 198 123 1·6 (1·4–1·9)
Men 239 506 person-years
All-cause mortality 70·5 (67·2–73·9) 1688 662 2·5 (2·4–2·7)
Non-AIDS deaths 41·1 (38·7–43·8) 986 651 1·5 (1·4–1·6)
Non-AIDS infections 5·6 (4·7–6·6) 134 23 5·8 (4·9–6·9)
Non-AIDS cancers 8·7 (7·6–10·0) 209 196 1·1 (0·93–1·2)
Cardiovascular disease and stroke 7·4 (6·4–8·6) 178 172 1·0 (0·89–1·2)
Liver disease 5·1 (4·3–6·1) 122 45 2·7 (2·3–3·2)
Accident 2·4 (1·8–3·1) 57 49 1·2 (0·88–1·5)
Suicide 2·3 (1·7–2·9) 54 36 1·5 (1·1–2·0)
Substance misuse 3·5 (2·9–4·4) 85 34 2·5 (2·0–3·1)
Other causes 6·1 (5·2–7·2) 147 96 1·5 (1·3–1·8)
Women 136 368 person-years
All-cause mortality 44·0 (40·6–47·7) 600 155 3·9 (3·6–4·2)
Non-AIDS deaths 21·2 (18·9–23·8) 289 152 1·9 (1·7–2·1)
Non-AIDS infections 4·7 (3·7–6·0) 64 6 10·7 (8·2–13·6)
Non-AIDS cancers 5·1 (4·1–6·5) 70 67 1·0 (0·81–1·3)
Cardiovascular disease and stroke 3·5 (2·7–4·7) 48 23 2·1 (1·5–2·8)
Liver disease 2·3 (1·7–3·3) 32 10 3·2 (2·2–4·5)
Accident 0·88 (0·50–1·5) 12 8 1·5 (0·77–2·6)
Suicide 0·29 (0·11–0·78) 4 5 0·80 (0·21–2·0)
Substance misuse 0·59 (0·29–1·2) 8 6 1·3 (0·57–2·6)
Other causes 3·7 (2·8–4·9) 51 27 1·9 (1·4–2·5)
*Numbers might not add up because of rounding.
Table 8: Crude and age-standardised mortality in HIV-positive individuals by sex, cause of death, after 
the ﬁ rst year of diagnosis
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